There are currently 1092 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Family Study of Lymphoproliferative Disorders
NCT00626496
Recruiting
Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development o... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/02/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Monoclonal B-Cell Lymphocytosis, Multiple Myeloma
Register for Updates
Oropharynx (OPX) Biomarker Trial
NCT06356272
Recruiting
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Head and Neck Carcinoma, Head and Neck Neoplasm, Salivary Gland Neoplasms, Thyroid Gland Neoplasm
Register for Updates
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547
Recruiting
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
11/26/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
Register for Updates
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Register for Updates
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Rochester, Minnesota
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Register for Updates
His Bundle Pacing in Bradycardia and Heart Failure
NCT03008291
Recruiting
Participants in this study will either have heart failure (HF) and are scheduled to undergo pace maker (PM) implantation, cardiac resynchronization therapy pacemaker (CRT-P), cardiac resynchronization therapy defibrillator (CRT-D) implantation, His bundle pacing (HIBP) or left bundle area pacing (LBAP) (including HIBP/LBAP for patients with HF, for patients who have failed CRT implant or patients who are CRT non-responders), or have atrioventricular (AV) block or bradycardia and are scheduled to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Bradycardia, Heart Failure
Register for Updates
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis
NCT05992883
Recruiting
The Researchers are trying to compare two different types of intraarticular injections (injection in the joint) for treating the symptoms of moderate to advanced basilar thumb arthritis. One injection is ketorolac (an NSAID) and the other is triamcinolone (a corticosteroid).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
11/22/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Thumb Osteoarthritis
Register for Updates
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Mayo Clinic in Minnesota, Rochester, Minnesota
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Register for Updates
AI-SCREENDCM Decentralized Clinical Trial - Pilot Study
NCT06609174
Recruiting
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cardiomyopathy
Register for Updates
Study of Transcranial Direct Current Stimulation to Treat Epilepsy
NCT05673915
Recruiting
The purpose of this research is to see to what extent electrical stimulation applied to the scalp (transcranial direct current stimulation or tDCS) can reduce the number and intensity of epileptic seizures.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
11/20/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Focal Epilepsy, Generalized Onset Epilepsy, Sleep-related Epileptic Encephalopathy
Register for Updates
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Non Small Cell Lung Cancer
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Myocarditis Acute, Cancer
Register for Updates